The government may extend the deadline for drug manufacturers to comply with revised Schedule M standards until December 2025 ...

Looking to the future, Suven’s Horizon 2 initiative – which includes plans to incorporate capabilities in flow chemistry, ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Japanese pharmaceutical company Eisai Co. and U.S. firm Biogen Inc. said Monday that a jointly developed Alzheimer's drug has been approved for continuous use for people with early stages of the ...

The Ibn Sina Pharmaceutical Industry's profit grew marginally in the second quarter of fiscal year 2024-25. The company's ...

The Ibn Sina Pharmaceutical Industry's profit grew marginally in the second quarter of fiscal year 2024-25. The company's profit stood at Tk 21.08 crore in Q2. Shares of the company went up 0.24 ...

Consumer sentiment declines for the first time in six months, semiconductor stocks drop 1.9% while pharmaceuticals gain. Asia rallies and Europe dips.

The Name of the Year for 2024, according to the American Name Society, is “Ozempic," as in “Ozempic face,” “oat-zempic” and ...